Covered
IRWD · Ironwood Pharmaceuticals, Inc.
Updated ·
Against its published line
Above its line on the last close.
How to read this
The red mark is the published kill line — the price that would prove the thesis wrong. The dot is where the name closed on the last session; a dot left of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row reads well clear, with a hollow dot to show the figure is off the drawn scale. Rows run tightest first.
Kill line
A daily close below $3.05, the price at which director Alexander Denner sold shares on 17 March 2026. A cut to 2026 revenue guidance of $460–485 million or adjusted EBITDA guidance of above $310 million would separately end the operating case.
Not a pickResearch coverage at low conviction. A medium-or-higher call would open a pick on the scoreboard.
Catalyst (7 days ago)
How picks are graded →The thesis
Ironwood Pharmaceuticals still earns a growing share of profit from LINZESS, a constipation drug sold by partner AbbVie, but the shares have kept falling and closed at $3.51 on 27 October 2026, 34.9% below the 52-week high of $5.39. AbbVie's third-quarter report on 30 October 2026 shows whether U.S. LINZESS net sales are still rising, and that settles whether the decline has an operating cause.
The operating evidence is unchanged since the last note. On 6 August 2026 management raised 2026 revenue guidance to $460–485 million and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) guidance to above $310 million. The one new item is leadership: Ironwood's 8-K and press release of 16 October 2026 name Chief Commercial Officer Tammi Gaskins as chief executive officer from 1 January 2027, succeeding Tom McCourt, who stays on the board. The adjusted daily close was $3.60 on 14 October 2026 and $3.51 on 27 October 2026, so the announcement did not lift the shares.
The narrative is maturing: the guidance raise is well known, the 10 September 2026 Wells Fargo conference added only reiterated guidance, and the succession news drew no visible buying. The rating stays low because the shares have lagged without a stated reason and the next two reports are the first hard tests of the raised guidance.
Bullish and bearish views on Ironwood Pharmaceuticals, Inc.
The bull case on Ironwood Pharmaceuticals, Inc. (IRWD), in brief: Reported profit is rising. The bear case: The shares keep falling without an operating reason.
Bull case
- Reported profit is rising. Second-quarter 2026 revenue was $113.0 million against $85.2 million a year earlier (Ironwood, 6 August 2026). U.S.
- Guidance was raised, not just held. Management lifted LINZESS U.S. net sales guidance to $1.15–1.20 billion on 6 August 2026. At the 10 September 2026 Wells Fargo conference it reiterated guidance and reported prescription demand growth of 5% through June.
- Debt is falling. The $200 million convertible note was repaid in cash at its June 2026 maturity (6 August 2026 call). Management's year-end target is gross debt below $300 million.
- Succession keeps the commercial lead in place. The board chose Gaskins, the executive who runs LINZESS sales, on 12 October 2026 (8-K, 16 October 2026). McCourt remains a director.
- Analyst targets sit far above the price. The average S&P Global analyst target was $6.10 as of 19 September 2026 (StockAnalysis). Only four analysts contribute, so the figure is a thin read.
Bear case
- The shares keep falling without an operating reason. The close slid from $4.36 on 18 September 2026 to $3.76 on 1 October 2026, $3.60 on 14 October 2026 and $3.51 on 27 October 2026 (adjusted daily bars). No filing or announcement in that window reports weaker sales.
- Quarterly revenue missed an estimate. Second-quarter revenue of $113.041 million compared with the $114.844 million estimate cited by Benzinga on 6 August 2026.
- Insiders have only sold in 2026. CFO Ronald Silver sold 127,890 shares at $4.52 on 7 July 2026, and director Alexander Denner sold 6,730,800 shares at $3.05 on 17 March 2026 (SEC Form 4).
- Apraglutide is a cost before it is a catalyst. STARS-2, the 24-week confirmatory Phase 3, has recruited since June 2026 with no guided readout date, and management cited a filing aim of 2029 on 10 September 2026.
- The strategic review is silent. A Goldman-run review has been open since April 2025 with no announced bidder. The 16 October 2026 succession release does not mention it.
Price setup
The adjusted daily close was $3.51 on 27 October 2026. That is below the $3.60 close of 14 October 2026 and the $3.76 close of 1 October 2026, and 34.9% under the 52-week high of $5.39. The 14-day relative strength index (RSI) was 40.3 on 27 October 2026, up from 25.2 on 14 October 2026. The three-month price change was -5.9%.
The $3.80 level in the previous note remains above the price. The nearest lower reference is $3.05, the price at which director Alexander Denner sold shares on 17 March 2026, which is also the invalidation level in this note.
Crowding evidence is light. No heavy retail attention or run-up above a rising average is visible, and insider activity in 2026 has been sales, not purchases. Earnings are the near-term event risk.
Catalysts, next 30 days
- ~5 November to 10 November 2026, est. Ironwood Q3 2026 results. The company has not confirmed a date. Earnings Whispers lists 5 November 2026 with a consensus EPS estimate of $0.30, Unusual Whales lists 9 November 2026 and AJ Bell lists 10 November 2026. The report tests the raised guidance and management's 6 August 2026 statement that quarterly sales rise sequentially.
- 31 December 2026 — Management debt target. Gross debt below $300 million.
- 1 January 2027 — CEO transition. Gaskins takes over from McCourt.
- ~5 January 2027, est. Initial 2027 guidance. Shows whether LINZESS sales hold above the 2026 level once the pricing and rebate gain is a year old.
Elapsed catalysts
- 30 October 2026 — AbbVie Q3 2026 results, before the market opens. AbbVie records U.S. LINZESS net sales, so the report reads the revenue line behind Ironwood's profit share. Sequential sales below the $282.3 million of Q2 2026 would count against the case. (passed 7d ago)
What would change the view
The operating case breaks if AbbVie or Ironwood reports sequential U.S. LINZESS net sales below the $282.3 million of Q2 2026, or if Ironwood lowers 2026 revenue guidance of $460–485 million or adjusted EBITDA guidance of above $310 million. A 2027 outlook that puts LINZESS below the 2026 range of $1.15–1.20 billion would also break it. On price, a daily close below $3.05 ends the thesis.
The case improves if the 30 October 2026 AbbVie report and the Ironwood Q3 report show LINZESS sales rising and guidance holding, which would give the share-price decline no operating support. A company statement ending the strategic review without a deal would remove a possible source of upside.
What it trades with
Ironwood's revenue depends on one drug marketed by AbbVie, so AbbVie's LINZESS disclosures move the shares more than sector indexes do. The shares are a small-cap, thinly covered stock with four analysts in the S&P Global poll, and they react to company-specific reports. The apraglutide programme adds exposure to clinical and cost news that is independent of LINZESS.
Notes
- Revenue is a collaboration share: AbbVie records U.S. LINZESS net sales ($282.3M in Q2 2026) and Ironwood booked $113.0M of total revenue that quarter.
- STARS-2 is a 24-week confirmatory apraglutide Phase 3 that began recruiting in June 2026, with no company-guided readout date. It is a cost line before it is a catalyst.
- Coverage is thin: 4 analysts in the S&P Global poll, and data aggregators disagree on whether Q2 2026 adjusted EPS beat or missed consensus.
- A Goldman-run strategic review has been open since April 2025 with no announced bidder.
- Tammi Gaskins becomes CEO on 1 January 2027, succeeding Tom McCourt, who stays on the board; Dr. Jeffrey Silber became Chief Medical Officer on 20 July 2026.